VLP


Also found in: Dictionary, Acronyms, Encyclopedia.

VHLL

A gene on chromosome 1q22 that encodes a protein which functions as a dominant-negative VHL (protein) to protect HIFalpha.

VLP

Virus-like particles, see there.
References in periodicals archive ?
The VLP values from El Neusa reservoir were within the same order of magnitude as those observed in lentic ecosystems of temperate and tropical latitudes with different trophic states, especially those with moderate to high levels of nutrients and biological productivity (Wilhelm & Smith, 2000; Bettarel et al.
Each well was coated with 100 ng of purified VLP or denatured VLP (produced by the addition of 0.
As we can see, VLP location recognition will be performed by ARM processor.
Netlist's new 16GB, 4Rank VLP module enables high-memory density by leveraging the benefits of the company's patented Planar-X technology.
Safety appears to be less of a concern than it is for VLPs, according to Dr.
Results: The recombinant protein was predominantly a ~55 KD species with distinct immunoreactivity and formed VLP as confirmed by electron microscopy.
After three days post challenge, animals immunized with the 15 mcg dose of the H1N1 VLP vaccine had no detectable virus recovered in nasal washes and showed no signs of disease.
De acuerdo al diseno experimental, se dividio a los animales de manera aleatoria, en 5 grupos (Tabla 1) , siendo el A el formado por 8 animales vacunados con VLP del serotipo 1 y desafiados con el mismo serotipo, el B, 6 animales vacunados con VLP 1+4 y desafiados con el serotipo 1, el C 3 animales sin vacunar a los que se infecto con el serotipo 1, grupo D compuesto por 6 animales vacunados con VLP 1+4 y desafiados con el serotipo 4 y finalmente, el grupo E compuesto por 3 animales a los que no se administro vacuna y que fueron desafiados con el serotipo 4
The new company, VLP Biotech Inc, would be established in cooperation with the Vaccine Research Institute of San Diego (VRISD), and would focus on developing a general vaccine against the Influenza A virus, as well as vaccines against Alzheimer's disease and for use in treating allergies, Tripep said.
If the efficacy and safety of these VLP vaccines are confirmed in larger trials now underway, they may be marketed to the public eventually, he reported at an international conference on malignancies in AIDS and other immunodeficiencies.
Analysis of the IgG1/IgG2a ratio indicated that a Th1-oriented immune response resulted from these VLP immunizations.
Biotechnology company VLP Therapeutics LLC reported on Wednesday the receipt of USD298,729 Phase I grant from the National Cancer Institute under auspices of the Small Business Innovation Research (SBIR) programme of the National Institutes of Health.